BioCryst Pharmaceuticals, Inc. (BCRX) Reports In-Line Q4 EPS
Tweet Send to a FriendGet Alerts BCRX Hot Sheet
Price: $1.79 +5.29%
Revenue Growth %: -70.5%
Financial Fact:
Research and development: 7.41M
Today's EPS Names:
CO, JW-A, FDS, More
Revenue Growth %: -70.5%
Financial Fact:
Research and development: 7.41M
Today's EPS Names:
CO, JW-A, FDS, More
Trade BCRX Now!
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q4 EPS of ($0.29), in-line with the analyst estimate of ($0.29). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $7.34 million.
BioCryst Pharmaceuticals, Inc. sees FY2012 EPS of (n/a). BioCryst Pharmaceuticals, Inc. sees FY2012 revenue of $5 million.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
BioCryst Pharmaceuticals, Inc. sees FY2012 EPS of (n/a). BioCryst Pharmaceuticals, Inc. sees FY2012 revenue of $5 million.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- La-Z-boy, Inc. (LZB) Tops Q4 EPS by 5c
- Five Below (FIVE) Tops Q1 EPS by 1c, Boosts FY13 Outlook
- UPDATE: Citi Raises PT on Micron Technology (MU) to $19
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
